{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lantern Pharma, Inc.
Is Lantern Pharma, Inc. technically bullish or bearish?
As of May 20, 2025, Lantern Pharma, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, Bollinger Bands, KST signals, and underperformance against the S&P 500.
Who are in the management team of Lantern Pharma, Inc.?
As of March 2022, the management team of Lantern Pharma, Inc. includes Mr. Donald Keyser (Independent Chairman), Mr. Panna Sharma (President and CEO), Dr. David Silberstein, Dr. Vijay Chandru, Mr. Leslie Kreis, and Dr. Franklyn Prendergast (all Independent Directors). They oversee the company's strategic direction and operations.
What does Lantern Pharma, Inc. do?
Lantern Pharma, Inc. is a clinical stage biotechnology company focused on developing oncology therapies, with a market cap of approximately $33.97 million and a quarterly net loss of $5 million as of March 2025. The company has no dividend yield and negative return on equity.
How big is Lantern Pharma, Inc.?
As of Jun 18, Lantern Pharma, Inc. has a market capitalization of 33.97 million and reported net sales of 0.00 million with a net profit of -19.89 million over the last four quarters. The balance sheet shows shareholder's funds of 21.19 million and total assets of 25.57 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
